TOP > 外国特許検索 > MOLECULAR MIMIC MUCOSAL AIDS VACCINE

MOLECULAR MIMIC MUCOSAL AIDS VACCINE コモンズ

外国特許コード F130007515
掲載日 2013年7月12日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP070724
国際公開番号 WO 2013024859
国際出願日 平成24年8月15日(2012.8.15)
国際公開日 平成25年2月21日(2013.2.21)
優先権データ
  • 特願2011-177385 (2011.8.15) JP
発明の名称 (英語) MOLECULAR MIMIC MUCOSAL AIDS VACCINE コモンズ
発明の概要(英語) The present invention addresses the problem of providing an AIDS vaccine whereby mucosal immunity can be induced, the immune system can be defended against breakdown by HIV infection, HIV can be prevented from escaping the immune system by being highly mutable, and rapid HIV infection can be prevented. According to the present invention, provided is an AIDS vaccine comprising a hub antigen and a complex of N2,N6-bis [N2,N6-bis(3,4,5-trihydroxybenzoyl)-L-lysyl]-N-(2-aminoethyl)-L‑lysinamide (TGDK) and fetuin.
従来技術、競合技術の概要(英語) BACKGROUND ART
1796 Year starts from the strains of the vaccine, the concept of vaccine made by the tool path, the vaccine is essential for biological defense. Vaccines that part of the molecular mechanism of defense is likely to be established, many points are unknown. Vaccine for side reactions also misleading to the point that, in the past improper methods of administration (for example, used on the injection needle or the like) by, a new infection (for example, such as hepatitis C) is also a problem that increase. In addition, the development of vaccines American HIV/AIDS has been be done, the success of the technology has not been developed yet.
On the other hand, in Patent Document 1, formula 1: TGDK-CH2 -CH2 -NH-R(formula, TGDK-CH2 -CH2 -NH-is, 2 - [N-α, N-ε-bis (N-α, group -digalloyllysinyl) lysinyl]aminoethylamino N-ε, is R, a hydrogen atom; via a peptide bond or a group having an active ester; SH group via a peptide bond group bonding to the; binding peptide via a peptide bond, protein, lipid or sugar: crystals or linked via a peptide, protein, lipid or sugar shown.) From the compound represented by the immunostimulatory agent is described in the intestinal tract. Patent Document 1 is, the above-identified TGDK M cells is described.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • LSIP, LLC
  • 発明者(英語)
  • MISUMI Shogo
  • SHOJI Shozo
  • TAKAMUNE Nobutoki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close